News
News
Academy
Multimedia
Editorial Podcasts
Editorial Videos
Peer Exchange
Profiles in Medicine
Shorts
Conferences
Conference Coverage
Conference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement Hubs
Events
Sponsored Podcasts
Sponsored Videos
Webcasts
Whitepapers
eBooks
Event Calendar
Subscribe
My Account
News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Event Calendar
Subscribe
Corporate Communications
Press Releases
Executive Roundtable
Executive Profiles
Leadership
Direct-to-Consumer
Patient Education
Healthcare Access
Telehealth
Emerging Biopharma
Partnerships
Funding
IR Licensing and Partnerships
Finance
Industry Trends
Market Access
Patient Access
Pricing
Strategy
Medical Affairs
Patient Advocacy
Clinical Data
Pharmacovigilance
Operations
Sustainability
Technology
R&D/Clinical Trials
Supply Chain
Patient Engagement
DE&I
Regulatory
FDA
Legal
Global
Sales & Marketing
Sales Effectiveness
Campaigns
DTC Marketing
Medical Education
Choose Topic
Spotlight -
Emerging Pharma Leaders Awards
|
Latest Executive Roundtables
|
Asembia 2026
|
Sales Effectiveness
Advertisement
News
Advertisement
Articles by News
Indian High Court Clears $4 BN Sun-Ranbaxy Merger
By
News
March 10th 2015
March 10, 2015.
Advertisement
Latest Updated Articles
Indian High Court Clears $4 BN Sun-Ranbaxy Merger
March 10th 2015
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5
Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie